www.tevaoctreotide.com Open in urlscan Pro
45.60.34.221  Public Scan

Form analysis
1 forms found in the DOM

GET /en/octreotide/search-result/

<form action="/en/octreotide/search-result/" class="gw-page-search__form" method="get" novalidate="" role="search">
  <fieldset class="gw-page-search__set">
    <label class="sr-only" for="sg-2d114b">Search</label>
    <input id="sg-2d114b" autocomplete="off" class="gw-page-search__input" data-tabindex-collapsed="4" placeholder="type your search" aria-label="type your search" required="" type="search" value="">
    <div class="gw-page-search__btn">
      <button type="submit" data-tabindex-collapsed="4" class="vi-btn vi-btn-search"> Search </button>
    </div>
  </fieldset>
  <div class="gw-page-search__clear">
    <div class="gw-page-search__clear-inset">
      <div class="gw-page-search__clear-btn">
        <button type="reset" class="vi-btn-search vi-btn-search--clear vi-btn"> Clear </button>
      </div>
    </div>
  </div>
</form>

Text Content

We recommend using a newer internet browser, such as Google Chrome or Microsoft
Edge, to optimize your browsing experience

Close

Skip to main content
Search
Search
Clear
Close
 * Full Prescribing Information

Search
 * About
 * Savings
 * How to Administer
 * FAQs
 * Teva's Commitment


Menu


   


TEVA OFFERS THE FIRST FDA-APPROVED GENERIC VERSION OF SANDOSTATIN®* LAR DEPOT

For the treatment of acromegaly, severe diarrhea/flushing episodes associated
with metastatic carcinoid tumors, and profuse watery diarrhea associated with
Vasoactive Intestinal Peptide (VIP) secreting tumors

Learn more Teva offers the first FDA-approved generic version of Sandostatin®*
LAR Depot


HOW TO ADMINISTER

Intended for Healthcare Professionals only. Learn the administration process for
Teva's Octreotide Acetate for Injectable Suspension, for gluteal intramuscular
use.

Watch video How to Administer


PAY AS LITTLE AS $10* FOR TEVA'S OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION,
FOR GLUTEAL INTRAMUSCULAR USE

*Eligibility requirements apply.

Download Savings Card Pay as little as $10* for Teva's Octreotide Acetate for
Injectable Suspension, for gluteal intramuscular use


TEVA KNOWS GENERICS - IT'S WHAT WE DO.

Find out how Teva became a leading producer of generics.

Read more Teva knows generics - it's what we do.

--------------------------------------------------------------------------------


IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT OCTREOTIDE ACETATE
FOR INJECTABLE SUSPENSION?

Treatment with octreotide acetate for injectable suspension may affect
gallbladder function, with reports of gallstones resulting in complications
(inflammation of the gallbladder, bile duct, and pancreas, and requiring
surgical removal of the gallbladder); sugar metabolism; thyroid and heart
function; and nutritional absorption, which may require monitoring by your
doctor. Tell your doctor if you experience signs or symptoms of gallstones or
any of their complications.

Patients with carcinoid tumors and VIP-secreting tumors should adhere closely to
their scheduled return visits for reinjection in order to minimize exacerbation
of symptoms. 

Patients with acromegaly should adhere to their return visit schedule to help
assure steady control of GH and IGF-1 levels.

WHAT SHOULD I TELL MY DOCTOR BEFORE TAKING OCTREOTIDE ACETATE FOR INJECTABLE
SUSPENSION?

Tell your doctor if you have a history of heart disease or are taking other
medications, including cyclosporine, insulin, oral hypoglycemic agents,
beta-blockers, and bromocriptine.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF OCTREOTIDE ACETATE FOR INJECTABLE
SUSPENSION?

In acromegalic patients, the most common side effects of octreotide acetate for
injectable suspension include gallstones, diarrhea, abdominal pain, gas,
flu-like symptoms, constipation, headache, low red blood cells, injection-site
pain, gallstones, high blood pressure, dizziness and fatigue.

In carcinoid tumor and VIP-secreting tumor patients, the most common side
effects of octreotide acetate for injectable suspension include back pain,
fatigue, headache, abdominal pain, nausea, and dizziness.

These are not all of the possible side effects of octreotide acetate for
injectable suspension. Call your doctor for medical advice about side effects.
You are encouraged to report side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

WHAT IS OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION?

Octreotide acetate for injectable suspension is a prescription medication used
in patients in whom initial treatment with octreotide acetate injection has been
shown to be effective and tolerated for:

 * Long-term maintenance therapy in acromegalic patients who have had an
   inadequate response to surgery and/or radiotherapy, or for whom surgery
   and/or radiotherapy, is not an option to reduce GH and IGF-1 levels to
   normal.
 * Long-term treatment of the severe diarrhea and flushing episodes associated
   with metastatic carcinoid tumors.
 * Long-term treatment of the profuse watery diarrhea associated with
   VIP-secreting tumors.

In patients with carcinoid tumors and VIP-secreting tumors, the effect of
octreotide acetate injection and octreotide acetate for injectable suspension on
tumor size, rate of growth and development of metastases, has not been
determined.

Please see the full Prescribing Information.

Toggle Instructions


IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT OCTREOTIDE ACETATE
FOR INJECTABLE SUSPENSION?

Treatment with octreotide acetate for injectable suspension may affect
gallbladder function, with reports of gallstones resulting in complications
(inflammation of the gallbladder, bile duct, and pancreas, and requiring
surgical removal of the gallbladder); sugar metabolism; thyroid and heart
function; and nutritional absorption, which may require monitoring by your
doctor. Tell your doctor if you experience signs or symptoms of gallstones or
any of their complications.

Patients with carcinoid tumors and VIP-secreting tumors should adhere closely to
their scheduled return visits for reinjection in order to minimize exacerbation
of symptoms. 

Patients with acromegaly should adhere to their return visit schedule to help
assure steady control of GH and IGF-1 levels.

WHAT SHOULD I TELL MY DOCTOR BEFORE TAKING OCTREOTIDE ACETATE FOR INJECTABLE
SUSPENSION?

Tell your doctor if you have a history of heart disease or are taking other
medications, including cyclosporine, insulin, oral hypoglycemic agents,
beta-blockers, and bromocriptine.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF OCTREOTIDE ACETATE FOR INJECTABLE
SUSPENSION?

In acromegalic patients, the most common side effects of octreotide acetate for
injectable suspension include gallstones, diarrhea, abdominal pain, gas,
flu-like symptoms, constipation, headache, low red blood cells, injection-site
pain, gallstones, high blood pressure, dizziness and fatigue.

In carcinoid tumor and VIP-secreting tumor patients, the most common side
effects of octreotide acetate for injectable suspension include back pain,
fatigue, headache, abdominal pain, nausea, and dizziness.

These are not all of the possible side effects of octreotide acetate for
injectable suspension. Call your doctor for medical advice about side effects.
You are encouraged to report side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

WHAT IS OCTREOTIDE ACETATE FOR INJECTABLE SUSPENSION?

Octreotide acetate for injectable suspension is a prescription medication used
in patients in whom initial treatment with octreotide acetate injection has been
shown to be effective and tolerated for:

 * Long-term maintenance therapy in acromegalic patients who have had an
   inadequate response to surgery and/or radiotherapy, or for whom surgery
   and/or radiotherapy, is not an option to reduce GH and IGF-1 levels to
   normal.
 * Long-term treatment of the severe diarrhea and flushing episodes associated
   with metastatic carcinoid tumors.
 * Long-term treatment of the profuse watery diarrhea associated with
   VIP-secreting tumors.

In patients with carcinoid tumors and VIP-secreting tumors, the effect of
octreotide acetate injection and octreotide acetate for injectable suspension on
tumor size, rate of growth and development of metastases, has not been
determined.

Please see the full Prescribing Information.

 
 * About Teva's Octreotide
 * Savings
 * How to Administer [HCP ONLY]

 * FAQs
 * Teva's Commitment to Generics
 * Full Prescribing Information

 * Legal Notice
 * Privacy Notice
 * Accessibility Statement

*Sandostatin® is a registered trademark of Novartis AG Corporation.

FOLLOW TEVA

 * Facebook
 * Linkedin

©2024 Teva Pharmaceuticals USA, Inc. | TG-43749 September 2024

Click here to go back to top



YOU ARE ABOUT TO LEAVE THIS SITE

Close

The website you are about to access may be governed by different regional
policies, regulations or advertising codes. Please be sure to read the privacy
policy and terms of use of the websites that you visit.

Teva Pharmaceuticals is not responsible for the accuracy or compliance with laws
of information on any third party websites.

Do you wish to proceed?

Go to site

By clicking “Accept All Cookies”, you agree to the storing of cookies on your
device to enhance site navigation, analyze site usage, and assist in our
marketing efforts.
Cookies Settings Accept All Cookies



PRIVACY PREFERENCE CENTER

When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information
Allow All


MANAGE CONSENT PREFERENCES

STRICTLY NECESSARY COOKIES

Always Active
Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.

PERFORMANCE COOKIES

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore may be
non-directly identifiable. If you do not allow these cookies we will not know
when you have visited our site, and will not be able to monitor its performance.

TARGETING COOKIES

Targeting Cookies

These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.

FUNCTIONAL COOKIES

Functional Cookies

These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies then some
or all of these services may not function properly.

Confirm My Choices

Back Button

Back


PERFORMANCE COOKIES



Vendor Search Search Icon Filter Icon


Clear Filters

Information storage and access
Apply
Consent Leg.Interest

All Consent Allowed

Select All Vendors
Select All Vendors
All Consent Allowed

Confirm My Choices